2002

82. Alvarez RD, Huh WK, Khazaeli MB (P6) , Meredith RF (P6) , Partridge EE, Kilgore LC, Grizzle WE (CC) , Shen S (P6) , Austin JM Jr, Barnes MN , Carey DE, Schlom J, LoBuglio AF (P2) : A phase I study of combined modality 90-yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8:2806-2811, 2002.

83. Alvarez J, Sohn P, Zeng X, Doetschman T, Robbins DJ, Serra R (PP) : TGF-beta-2 mediates the effects of hedgehog on hypertrophic differentiation and PTHrP expression. Development 129:1913-1924, 2002.

84. Arafat WO, Gomez-Navarro J, Buchsbaum DJ (P5) , Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN , Siegal GP (CB) , Alvarez RD , Hemminki A (CD) , Nettelback DM, Curiel DT (P4) : Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy 9:256-262, 2002.

85. Barnes MN, Berry WD, Straughn JM, Kirby TO, Leath CA , Huh WK, Grizzle WE (CC) , Partridge EE: A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol 87:57-63, 2002.

86. Barnes MN, Coolidge CJ, Hemminki A (CD) , Alvarez RD, Curiel DT (P4) : Conditionally replicative adenoviruses for ovarian cancer therapy. Mol Cancer Ther 1:435-439, 2002.

87. Barnes MN, Grizzle WE (CC) , Grubbs CJ (P1) , Partridge EE: Paradigms for primary prevention of ovarian carcinoma. Ca: A Cancer Journal for Clinicians 52:216-225, 2002.

88. Barnett BG, Tillman BW, Curiel DT (P4) , Douglas JT: Dual targeting of adenoviral vectors at the levels of transduction and transcription has a synergistic effect on the specificity of gene expression in cancer cells. Molec Therapy 6:377-385, 2002.

89. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I (CD) , Krasnykh VN (PP) , Mikheeva GV, Barnes MN , Alvarez RD , Dall P, Alemany R, Curiel DT (P4) , Hemminki A (CD) : Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 62:1266-1270, 2002.

90. Beenken SW (CA, P1) , Bland KI (CA) : Advanced breast carcinoma (stage IIIA&B). In: Bland KI (ed), The Practice of General Surgery. W.B. Saunders, Philadelphia , PA , pp. 979-984, 2002.

91. Beenken SW (CA, P1) , Bland KI (CA) : Biomarkers for breast cancer. Minerva Chirurgica ( Italy ) 57:437-448, 2002.

92. Beenken SW (CA, P1) , Bland KI (CA) : Breast-conserving surgery: Lumpectomy with or without axillary dissection. In: Torosian M (ed), Breast Cancer: Multidisciplinary Management. Humana Press, Totowa , NJ , pp. 89-98, 2002.

93. Beenken SW (CA, P1) , Bland KI (CA) : Long-term complications of breast-conservation therapy: Can the incidence be reduced? Ann Surg Onc 9:524-525, 2002.

94. Beenken SW (CA, P1) , Grizzle WE (CC) , Crowe DR, et al.: Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53. In: Copeland EM III (ed), Year Book of Surgery, 2002 Edition. Mosby Yearbook, St. Louis , MO , Chapter 11-1, pp. 305-307, 2002.

95. Beenken SW (CA, P1) , Hockett RD Jr, Grizzle WE (CC) , Weiss HL, Pickens A, Perloff M, Malone WF, Bland KI (CA) : Transforming growth factor-alpha: A valid surrogate endpoint biomarker? J Amer Coll Surg 195:149-158, 2002.

96. Belousova N, Krendelchtchikova V, Curiel DT (P4) , Krasnykh VN (PP) : Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 76:8621-8631, 2002.

97. Bland KI (CA) : Lobular carcinoma in situ and invasive cancer: The management controversy. Breast J 8:261-262, 2002.

98. Bland KI (CA) : Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Onc 9:217-219, 2002.

99. Bryant R, Tollefsbol TO (PP) : The effects of all-trans 9-cis and UAB30 retinoic acids on human breast cancer cells. McNair Chronicle 3:24-26, 2002.

100. Buchsbaum DJ (P5) , Rogers BE, Khazaeli MB (P6) , Carpenter DM, Safavy A: Treatment of tumor xenografts with 177-Lu and 188-Re-HuCC49 and HuCC49 and HuCC4-delta-CH2. J Nucl Med 43:268P, 2002.

101. Carpenter DM, Buchsbaum DJ (P5) : Statistical growth curve modeling of tumors treated with ERBITUX (IMC-C225) anti-EGFR antibody, gemcitabine and radiation. Proc AACR 43:1005-1006, 2002.

102. Chaudhuri TR, Cao Z, Della Manna DL, Rodriguez-Burford C (CC) , Partridge EE, Zinn KR (CD) : A sensitive method for treatment monitoring of microscopic ovarian cancer in live mice. Mol Ther 5:S115, 2002.

103. Chaudhuri TR, Cao Z, Partridge EE, Zinn KR (CD) : A comparative analyses of light-based and gamma-camera imaging to detect non-palpable ovarian cancer lesion in nude mice. Mol Ther 5:S270, 2002.

104. Chaudhuri TR, Cao Z, Partridge EE, Zinn KR (CD) : A comparative analysis of optical and gamma camera imaging for non-invasive detection of ovarian cancer. Eur J Nuc Med Mol Imaging 29:S229, 2002.

105. Chaudhuri TR, Cao Z, Rodriquez-Burford C, LoBuglio AF (P2) , Zinn KR (CD) : A non-invasive approach for monitoring breast tumor cells during therapeutic intervention. Cancer Biother Radiopharm 17:205-212, 2002.

106. Chaudhuri TR, Krasnykh VN (PP) , Cao Z, Zinn KR (CD) : Dualistic genetic reporter system for early diagnosis and monitoring of ovarian cancer. Mol Ther 5:S207, 2002.

107. Christov K, You M, Grubbs CJ (P1) , End D, Lubet RA: Exceptional sensitivity of MNU-induced breast carcinomas in rats to farnesyl transferase inhibitors. Proc Am Assoc Cancer Res 43:513, 2002.

108. Cope MB, Steele VE, Eto I, Juliana MM, Hill DL (P1) , Grubbs CJ (P1) : Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3. Oncology Rep 9:533-537, 2002.

109. Dmitriev IP (CD) , Kashentseva EA, Curiel DT (P4) : Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 76:6893-6899, 2002.

110. Ellis RJ, Fabian CJ, Kimler BF (PP) , Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP: Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Res Treat 71:95-102, 2002.

111. Eltoum IE, Siegal GP (CB) , Frost AR (CC, P2, P3) : Microdissection of histologic sections: Past, present and future. Adv Anatomic Path 9:316-322, 2002.

112. Fabian CJ, Kimler BF (PP) : Breast cancer chemoprevention: Current challenges and a look toward the future. Clin Breast Cancer 3:113-124, 2002.

113. Fabian CJ, Kimler BF (PP) : Chemoprevention of breast cancer: Implications for postmenopausal women. Drugs & Aging 19:43-78, 2002.

114. Fabian CJ, Kimler BF (PP) , Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton AL , Masood S, Grizzle WE (CC) , Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer chemoprevention trial of oral alpha-DFMO: Breast tissue, imaging and serum and urine biomarkers. Clin Cancer Res 8:3105-3117, 2002.

115. Fabian CF, Lukert B, Chamberlain C, Anderson J, Mayo MS, Kimler BF (PP) , Johnson KA: Effects of arzoxifene, a third generation SERM, on serum osteocalcin levels and bone mineral density in pre- and post-menopausal women at increased risk for breast cancer. Proc Am Assoc Cancer Res 43:822, 2002.

116. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI (CA) : Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Molec Endocrinol 16:70-84, 2002.

117. Frost AR (CC, P2, P3) : In situ lobular carcinoma, atypical lobular hyperplasia and infiltrating lobular carcinoma. In: Silverberg S (ed), Atlas of Breast Pathology. W.B. Saunders , New York , pp. 100-116, 2002.

118. Grizzle WE (CC) , Mountz JD, Yang PA, Xu X, Sun S, Van Zant GE, Williams RW, Hsu HC, Zhang HG: BXD recombinant inbred mice represent a novel T cell-mediated immune response tumor model. Int J Cancer 101:270-279, 2002.

119. Haviv YS, Takayama K, Glasgow J, Blackwell JL, Li H, Wang M, Lei X, Curiel DT (P4) : A model system for armed therapeutic viruses using p53 as a candidate transgene. Mol Cancer Ther 1:321-328, 2002.

120. Hemminki A (CD) , Wang M, Desmond RA, Strong TV (PP) , Alvarez RD , Curiel DT (P4) : Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Human Gene Therapy 13:1505-1514, 2002.

121. Hemminki A (CD) , Zinn KR (CD) , Liu B, Chaudhuri TR, Desmond RA, Rogers BE, Barnes MN, Alvarez RD, Curiel DT (P4) : In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 94:741-749, 2002.

122. Isayeva T, Kotova O, Curiel DT (P4) , Kotov A: The production of adenoviral vectors for gene therapy in microcarrier culture under cGLP conditions. Mol Ther 5:196, 2002.

123. Jewell SD, Srinivasan M, McCart LM, Williams N, Grizzle WE (CC) , LiVolsi V, MacLennan G, Sedmak DD: Analysis of the molecular quality of human tissues: An experience from the Cooperative Human Tissue Network. Am J Clin Pathol 118:733-741, 2002.

124. Jones CL, Fish F, Muccio DD (P1) : Determination of RNase A/2'-cytidine monophosphate binding affinity and enthalpy by a global fit of thermal unfolding curves. Analytical Biochem 302:184-190, 2002.

125. Kanerva A, Mikheeva GV, Krasnykh VN (PP) , Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN , Alvarez RD , Hemminki A (CD) , Curiel DT (P4) : Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8:275-280, 2002.

126. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN , Alvarez RD , Siegal GP (CB) , Curiel DT (P4) , Hemminki A (CD) : Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 5:695-704, 2002.

127. Kashentseva EA, Seki T, Curiel DT (P4) , Dmitriev IP (CD) : Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 62:609-616, 2002.

128. Kim M, Zinn KR (CD) , Barnett BG, Sumerel LA, Krasnykh VN (PP) , Curiel DT (P4) , Douglas JT: The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38:1917-1926, 2002.

129. Kim S-O, Loesch K, Wang X, Jiang J, Mei L (PP) , Cunnick JM, Wu J, Frank SJ: A potential role for Grb2-associated binder (Gab)-1 in growth hormone signaling. Endocrinology 143:4856-4867, 2002.

130. Kruyt FA, Curiel DT (P4) : Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Human Gene Therapy 13:485-495, 2002.

131. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L (PP) , Kim TW: Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277:6318-6323, 2002.

132. Lopatina N, Haskell JF, Andrews LG, Poole JC, Saldanha S, Tollefsbol TO (PP) : Differential maintenance and de novo methylating activity by three DNA methyltransferases in aging and immortalized fibroblasts. J Cell Biochem 84:324-334, 2002.

133. Louro ID, Bailey EC, Li X, South LS, McKie-Bell PR, Yoder BK, Huang CC, Johnson MR (P2) , Hill AE, Johnson RE, Ruppert JM (P3) : Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 62:5867-5873, 2002.

134. Luo ZG, Wang Q, Zhou JZ, Wang J, Luo Z, Liu M, He X, Wynshaw-Boris A, Xiong WC, Lu B, Mei L (PP) : Regulation of AChR clustering by disheveled interacting with MuSK and PAK1. Neuron 35:489-505, 2002.

135. MacLennan PA, Delzell ES, Sathiakumar N, Meyers SL, Cheng H, Grizzle WE (CC) , Chen VW, Wu XC: Cancer incidence among triazine herbicide manufacturing workers. J Occup Environ Med 44:1048-1058, 2002.

136. Medina-Franco H, Vasconez LO, Fix RJ, Heslin MJ, Beenken SW (CA, P1) , Bland KI (CA) , Urist MM: Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 235:814-819, 2002.

137. Ohtsuka T, Zhou T (P5) : Bisindolylmaleimide VII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem 277:294-303, 2002.

138. Pereboev AV, Asiedu C, Kawakami K, Dong SS, Blackwell JL, Kashentseva EA, Triozzi PL (P5) , Aldrich WA , Curiel DT (P4) , Thomas JM, Dmitriev IP (CD) : Coxsackie virus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Therapy 9:1189-1193, 2002.

139. Piyathilake CJ, Oelschlager DK, Bell WC, Meleth S, Heimburger DC , Grizzle WE (CC) : Food fortification with folate: Has it benefited cancer prevention and control? FASEB J 16 (Part 1):A268, 2002.

140. Ponnazhagan S, Aleksandr P, Mahendra G, Curiel DT (P4) , Kleinschmidt J: Conjugate-based targeting of adeno-associated virus vectors. In: Douglas JTD, Curiel DT (eds), Vector Targeting for Therapeutic Gene Delivery. John Wiley and Sons, pp. 210-219, 2002.

141. Posey JA, Khazaeli MB (P6) , Bookman MA, Nowrouzi A, Grizzle WE (CC) , Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF (P2) , Saleh MN : A phase I trial of the single chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 8:3092-3099, 2002.

142. Robles LD, Frost AR (CC, P2, P3) , Davila M, Hutson AD, Grizzle WE (CC) , Chakrabarti R: Down regulation of Cdc6 transcription, a cell cycle regulatory gene, in prostate cancer. J Biol Chem 277:25431-25438, 2002.

143. Rodriguez-Burford C (CC) , Barnes MN , Oeschlager DK, Myers RB, Talley LI (PP) , Partridge EE, Grizzle WE (CC) : Effects of non-steroidal anti-inflammatory agents (NSAIDS) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDS as chemopreventive agents. Clin Cancer Res 8:202-209, 2002.

144. Rodriguez-Burford C (CC) , Steele VE, Anderson A, Stockard CR, Weiss HL, Eto I, Johanning GL, Grizzle WE (CC) , Grubbs CJ (P1) : Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology. J Nutr Cancer 43:67-75, 2002.

145. Seki T, Dmitriev I (CD) , Kashentseva E, Takayama K, Rots M, Suzuki K, Curiel DT (P4) : Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines. J Virol 76:1100-1108, 2002.

146. Seki T, Dmitriev I (CD) , Suzuki K, Kashentseva E, Takayama K, Rots M, Uil T, Wu H, Wang M, Curiel DT (P4) : Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Therapy 9:1101-1108, 2002.

147. Shen S (P6) , Duan J, Meredith RF (P6) , Buchsbaum DJ (P5) , Brezovich IA , Pareek PN, Bonner JA: Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer 94 (Suppl 4):1264-1269, 2002.

148. S hen S (P6) , Meredith RF (P6) , Duan J, Macey DJ, Khazaeli MB (P6) , Robert F, LoBuglio AF (P2) : Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow targeting 90-Y-antibody therapy. J Nucl Med 43:1245-1253, 2002.

149. Shen S (P6) , Meredith RF (P6) , Duan J, Robert F, Khazaeli MB (P6) , LoBuglio AF (P2) : Impact of patient-specific mass on liver dosimetry for radioimmunotherapy. J Nucl Med 43:86, 2002.

150. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI (CA) , Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Onc 20:3628-3636, 2002.

151. Suzuki K, Alemany R, Yamamoto Y (P4) , Curiel DT (P4) : The presence of the adenovirus E3 improves the oncolytic potency of conditionally replicative adenoviruses. Clin Can Res 8:3348-3359, 2002.

152. Talley LI (PP) , Grizzle WE (CC) , Waterbor JW, Brown D, Weiss HL, Frost AR (CC, P2, P3) : Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and post-menopausal women. Int J Cancer 98:118-127, 2002.

153. Vickers SM, Jhala NC , Ahn EY, McDonald JM, Pan G, Bland KI (CA) : Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma). Ann Surg 235:872-878, 2002.

154. Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, Zhang R (P1) , Hill DL (P1) : Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemotherapy & Pharmacology 49:419-424, 2002.

155. Wu H, Dmitriev I (CD) , Kashentseva E, Seki T, Wang M, Curiel DT (P4) : Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76:12775-12782, 2002.

156. Wu H, Siki T, Dmitriev I (CD) , Uil T, Kashentseva E, Han T, Curiel DT (P4) : Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Human Gene Therapy 13:1647-1653, 2002.

157. Zaliauskiene L, Fazio RL, Kang S, Sparks K, Zinn KR (CD) , Weaver CT , Collawn JF: Inhibition of T cell responses by transferrin-coupled competitor peptides. Immunol Res 26:77-85, 2002.

158. Zaliauskiene L, Kang S, Sparks K, Zinn KR (CD) , Schwiebert LM, Weaver CT , Collawn JF: Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. J Immunol 169:2337-2345, 2002.

159. Zhang HG, Xie J, Xu L, Yang P, Xu X, Sun S, Wang Y, Curiel DT (P4) , Hsu HC, Mountz JD: Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J Virol 76:5692-5700, 2002.

160. Zhou T (P5) , Mountz JD Jr, Kimberly RP: Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res 26:323-336, 2002.

161. Zinn KR (CD) , Cao Z, Ma Z, Chaudhuri TR: Detection of ovarian cancer with a new plasmid vector encoding two reporters: Blood-based screening combined with imaging. Mol Ther 5:S77, 2002.

162. Zinn KR (CD) , Chaudhuri TR: Imaging adenovirus-mediated gene transfer. In: Curiel DT, Douglas JT (eds), Adenoviral Vectors for Gene Therapy. Academic Press, 2002.

163. Zinn KR (CD) , Chaudhuri TR: The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med 29:388-399, 2002.

164. Zinn KR (CD) , Chaudhuri TR, Krasnykh VN (PP) , Buchsbaum DJ (P5) , Belousova N, Grizzle WE (CC) , Curiel DT (P4) , Rogers BE: Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 223:417-425, 2002.

165. Zinn KR (CD) , Krasnykh VN (PP) , Cao Z, Chaudhuri TR: Dual genetic reporter system for early diagnosis and monitoring of breast cancer. Breast Cancer Res Treat 76:S100, 2002.